军事知识服务平台
弓形虫视网膜脉络膜炎的临床特征和疗效观察
Clinical characteristics and therapeutic effects of toxoplasma retinal chorioretinitis
摘要 目的:观察弓形虫视网膜脉络膜炎(TRC)的临床特征及治疗效果。方法:回顾性临床病例研究。2022年10月至2026年5月于成都爱迪眼科医院检查确诊的TRC患者17例(21只眼)纳入研究。其中,男性8例,女性9例;单眼发病13例,双眼发病4例。患者年龄(35.10±19.38)岁,病程3 d~6个月。21只眼中,活动性病灶眼17只,陈旧性病灶眼4只(均为双眼患者的对侧眼)。所有患眼均行最佳矫正视力(BCVA)、眼底彩色照相、光相干断层扫描检查,以及血清和眼房水弓形虫特异性抗体检测。明确诊断前予以经验性抗弓形虫治疗,血清学及实验室检测确诊后维持原治疗方案。17例患者中,口服复方磺胺甲噁唑13例,口服阿奇霉素4例。治疗后随访时间1.5~6.0个月。回顾性分析患者的临床表现特征及治疗预后。结果:17只活动性病灶眼均可见玻璃体混浊及炎性细胞。视网膜病灶多位于后极部,以黄斑周围分布为主。活动性病灶(17只眼)多表现为形态不规则、边界模糊的灰白色浸润灶,其中累及视网膜神经上皮内层者14只眼,外层者3只眼;陈旧性病灶(4只眼)表现为视网膜萎缩、瘢痕形成及视网膜色素上皮(RPE)层改变。初诊时BCVA为数指至1.0,其中数指者3只眼,均与黄斑中心凹受累相关。治疗后,活动性病灶炎性反应消退,水肿吸收,病灶趋于平息并结瘢;神经上皮内层受累者可见结构变薄、瘢痕化及视网膜前增生膜形成,外层受累者则见RPE及脉络膜浅层瘢痕形成。BCVA显著提高者14只眼,但累及黄斑中心凹的3只眼视力恢复不佳。本组中1只眼因误诊为淋巴瘤延误治疗,最终发生眼球萎缩。结论:TRC以玻璃体混浊及后极部视网膜浸润为主要特征;治疗后炎症可消退,但黄斑中心凹受累是视力预后差的主要原因,延误诊治可致眼球萎缩。早期诊断和及时有效治疗是改善预后的关键。
Abstract:
Objective:To investigate the clinical characteristics and treatment outcomes of toxoplasmic retinochoroiditis (TRC).Methods:A retrospective clinical case study. From October 2022 to May 2026, 17 patients (21 eyes) diagnosed with TRC at Chengdu Aidi Eye Hospital were included in the study. Among them, there were 8 males and 9 females; 13 cases were unilateral and 4 cases were bilateral. The patients' age was (35.10±19.38) years old, and the disease duration ranged from 3 days to 6 months. Among the 21 eyes, 17 were active lesion eyes and 4 were old lesion eyes (all in the contralateral eyes of patients with bilateral involvement). All affected eyes underwent best corrected visual acuity (BCVA) testing, fundus color photography, optical coherence tomography examination, as well as serological and aqueous humor arthropod-specific antibody. Empirical anti-toxoplasma treatment was given before a definite diagnosis was made. After serological and laboratory tests confirmed the diagnosis, the original treatment plan was maintained. Among the 17 patients, 13 patients received oral sulfamethoxazole and azithromycin, and 4 patients received oral azithromycin. The follow-up period after treatment was 1.5 to 6.0 months. The clinical manifestations and treatment outcomes of the patients were retrospectively analyzed.Results:Vitreous opacity and inflammatory cells were observed in all 17 eyes. Retinal lesions were predominantly located in the posterior pole, mainly around the macula. Among the 17 eyes with active lesions, most showed irregularly shaped, ill-defined, grayish-white infiltrative lesions; the inner and outer retinal neuroepithelial layers were involved in 14 and 3 eyes, respectively. The 4 eyes with old lesions showed retinal atrophy, scarring, and changes in the retinal pigment epithelium (RPE) layer. At initial presentation, BCVA ranged from counting fingers to 1.0; 3 eyes had counting-finger vision, all associated with foveal involvement. After treatment, the inflammatory response in active lesions subsides, edema resolves, and the lesions gradually become quiescent and scarred; involvement of the inner neuroepithelial layer led to structural thinning, scarring, and formation of preretinal proliferative membranes, whereas those with outer layer involvement showed RPE and superficial choroidal scar formation. BCVA improved significantly in 14 eyes, whereas visual recovery was poor in the 3 eyes with foveal involvement. The BCVA significantly improved in 14 eyes, but the vision recovery was poor in 3 eyes that affected the macular fovea. In this group, 1 eye was misdiagnosed as lymphoma and the treatment was delayed, eventually resulting in eyeball atrophy.Conclusions:TRC is mainly characterized by vitreous opacity and posterior pole retinal infiltration; after treatment, the inflammation can subside, but the involvement of the macular fovea is the main reason for poor visual prognosis. Delayed diagnosis and treatment can lead to eyeball atrophy. Early diagnosis and timely effective treatment are crucial for improving prognosis.